Evaluation of Erythroferrone as a New Biomarker of Erythropoesis Stimulating Agents

Evaluation of Erythroferrone as a New Biomarker of Erythropoesis Stimulating Agents

The main objective of this research is to demonstrate the possible use of erythroferrone (ERFE) as a potential marker of recombinant human erythropoietin (rHuEpo) use to be included in the Athlete Biological Passport (PBA) developed by the World Anti-Doping Agency (WADA).

Inclusion Criteria:

• Man between 18 and 49 years old
• Beneficiary of a social protection scheme
• Able to sign informed consent

Exclusion Criteria:

• Hematocrite>50% or Hemoglobin> 17d/dl or Ferritin<30 ug/l
• Hypersensitivity to the active substance or to any of the excipients ofEPREX
• Erythroblastopenia already reported following treatment with erythropoietin
• Uncontrolled hypertension
• Any medication taken as part of a chronic treatment
• Absence of stable or evolutionary pathology without treatment
• History of convulsion or epilepsy
• History of thrombotic vascular events
• Large blood loss due to an accident, pathological condition or other similar situation.
• Donation of blood or blood transfusion within three months prior to inclusion in the protocol.